Joseph Renzulli, MD
Urology · Providence, RINPI 1538108832
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $48,609 of the $80,932 with a category attached, or 60.1%. It is spread thinly across 32 manufacturers, the largest accounting for just 22.5%. Reporting peaked in 2019 at $28,933 and has fallen 97.0% since, to $869 in 2025. Among urology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $535.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$18K
- Boston Scientific$17K
- Intuitive Surgical$10K
- Bayer$8K
- Astellas US LLC$7K
- Sanofi$5K
- plus $16K from 26 others
Across 68 payments — averaging $5749.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dendreon Pharmaceuticals LLC$216K
- Astellas Pharma Global Development$115K
- Janssen Research & Development, LLC$61K
What the payments were for
- Consulting fees$48,60960%
- Speaking & faculty fees$23,82529%
- Travel & lodging$3,8115%
- Food & beverage$4,5846%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 22 | $18,244 |
| Boston Scientific | 18 | $16,873 |
| Intuitive Surgical | 12 | $10,082 |
| Bayer | 22 | $8,130 |
| Astellas US LLC | 2 | $7,375 |
| Sanofi | 4 | $4,693 |
| Astellas Pharma Global Development | 2 | $3,260 |
| Dendreon Pharmaceuticals LLC | 8 | $3,096 |
| Tolmar Pharmaceuticals, Inc. | 5 | $2,405 |
| Astellas Pharma Europe Ltd | 1 | $2,048 |
| AstraZeneca | 2 | $1,895 |
| Urogen Pharma, Inc. | 7 | $725 |
| Procept Biorobotics Corporation | 1 | $317 |
| Teleflex LLC | 2 | $291 |
| Ferring Pharmaceuticals Inc. | 5 | $223 |
| Johnson & Johnson | 11 | $175 |
| Immunitybio, Inc. | 1 | $174 |
| EDAP Technomed Inc | 2 | $166 |
| Telix Pharmaceuticals | 1 | $144 |
| Myovant Sciences Inc. | 2 | $107 |
| Pfizer | 4 | $70 |
| Blue Earth Diagnostics | 3 | $63 |
| Palette Life Sciences, Inc. | 1 | $63 |
| Progenics Pharmaceuticals, Inc. | 1 | $62 |
| Merck | 3 | $61 |
| Koelis Inc. | 1 | $41 |
| AbbVie | 2 | $31 |
| Sun Pharmaceutical Industries Inc. | 2 | $29 |
| Covidien LP | 1 | $28 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Ambu Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$30,603
- GENERAL - THERAPIES$9,568
- DA VINCI SP$8,000
- Non-Covered$6,319
- JEVTANA$4,543
- SPACEOAR$3,600
- GENERAL BPH$3,150
- PROVENGE$2,997
- ELIGARD$2,275
- Da Vinci Surgical System$1,958
- LYNPARZA$1,880
- Nubeqa$1,389
- JELMYTO$562
- AquaBeam Robotic System$317
- ILLUCCIX$287
- ANKTIVA$174
- LithoVue$172
- Barrigel$149
- ADSTILADRIN$147
How this compares
$80,932 in reported general payments places this provider in the 95th percentile of 55 urology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 74 | $57,552 |
| MyrbetriqMirabegron | 30 | $13,921 |
| Finasteride | 153 | $2,282 |
| Tamsulosin Hcl | 106 | $1,598 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 71 | $1,524 |
| Tadalafil | 12 | $231 |
| Levofloxacin | 21 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $26 | $57,55274 claims |
| Astellas Pharma US IncMyrbetriq | $18,244 | $13,92130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 55 urology providers in Rhode Island.
Other urology in Providence
- Dicken KoProvidence$158K
- Gyan PareekProvidence$83K
- Simone ThavaseelanProvidence$16K
- Boris GershmanProvidence$13K
- Janice Santos CortesProvidence$12K
- Dragan GolijaninProvidence$11K
- Elias HyamsProvidence$10K
- Andrew TompkinsProvidence$3K
- Ashley MatthewProvidence$3K
- Gabriella AvellinoProvidence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.